Orexigen adopts corporate realignment
Orexigen adopted this course of action following the receipt of complete response letter from the US Food and Drug Administration on 31 January 2011 regarding the new drug
WuXi XDC Cayman has signed an agreement to provide Ona Therapeutics with an exclusive global licence to its WuXiTecan-2 payload-linker technology platform for the development of an antibody-drug conjugate (ADC) candidate.
Boehringer Ingelheim will carry out the technical development, clinical manufacturing and all related regulatory filing support services for antibodies discovered by Elan. Elan will guide the discovery science,